Beiersdorf
This article was originally published in The Rose Sheet
Executive Summary
North America was a sweet spot for the German firm in the first nine months of 2010, with consumer product sales in the region growing 13.2% organically (19% at current exchange rates) to €265 mil., firm reports Nov. 4. Nivea body care and shower products were particularly strong in North America during the January-September period, and Eucerin and La Prairie skin care achieved "encouraging growth," the firm says. The results suggest the company's "Focus On Skin Care. Closer to Markets" strategy is paying off in the Americas, Beiersdorf says, noting it now aims to strengthen its other business regions via the same strategy, which was announced in April (1"The Rose Sheet" April 5, 2010). Sales of the firm's consumer products in Europe decreased 1.5% during the nine-month period to €2.52 bil. Net sales for consumer products were up 2.3% for the period to €4.05 billion and operating results rose 10.4% to €467 mil., compared with the same period a year ago. For the full year, Beiersdorf projects total consumer business segment sales will increase about 2%
You may also be interested in...
Beiersdorf to focus on skin care
Expecting uneven international growth, increased competition from private label and consumers opting for lower-priced goods in the next few years, Hamburg, Germany firm decides to focus its efforts on skin care and addressing regional customer markets, according to a March 31 release. Fifty percent of anticipated global growth in the cosmetics market will be in skin care, says Beiersdorf Chairman Thomas-B. Quaas. "This translates into excellent growth opportunities for Beiersdorf, because skin care has always been our core competence," he adds. Firm also announced executive board organizational changes. Former Human Resources leader Peter Kleinshcmidt will leave the company; Bernhard Duttmann will take on his duties and maintain his position as finance chief. Markus Pinger will oversee the Americas region as well as the global supply chain, James C. Wei will oversee the firm's Asian business and a new board member will be named for Europe
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.